← Product Code [DSI](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DSI) · K070260

# STAR ST AND ARRHYTHMIA SOFTWARE, RELEASE H.0 (K070260)

_Philips Medical Systems · DSI · Feb 23, 2007 · Cardiovascular · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DSI/K070260

## Device Facts

- **Applicant:** Philips Medical Systems
- **Product Code:** [DSI](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DSI.md)
- **Decision Date:** Feb 23, 2007
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 870.1025
- **Device Class:** Class 2
- **Review Panel:** Cardiovascular
- **Attributes:** Software as a Medical Device, Pediatric

## Indications for Use

Where the clinician decides to monitor cardiac arrhythmia of adult, pediatric, and neonatal patients and/or ST segment of adult patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms. The intended use of the ST/AR cardiotach is to monitor a neonatal, pediatric, or adult patient's ECG for heart rate and produce events/alarms for one or two ECG leads. The cardiotach function is capable of monitoring both paced and non-paced patients. The intended use of the ST/AR arthythmia analysis algorithm is to monitor a neonatal, pediatric, or adult patient ECG's for heart rate and ventricular arrhythmias and produce events/alarms for one or two ECG leads. The arrhythmia analysis algorithm is capable of monitoring both paced and non-paced patients. The intended use of the ST/AR ST analysis algorithm is to monitor an adult patient's ECG for ST segment elevation or depression and produce events/alarms for all possible ECG leads. The ST analysis algorithm is capable of monitoring paced and non-paced adult patients. The ST algorithm does not analyze ventricularly paced or ventricular ectopic Note: beats. The intended use of the ST/AR QT/QTc analysis is for use by the physician in the risk assessment process indicated for neonatal, pediatric and adult patients with and without symptoms of arrhythmia. QT measurement is intended to be used by qualified health professionals in hospital or clinical environments. Composite QT (single or multi-lead derived) measures the interval only and is not intended to produce any interpretation or diagnosis of those measurements.

## Device Story

Software-based cardiac monitoring system; processes ECG signals to detect heart rate, arrhythmias, ST segment changes, and QT/QTc intervals. Operates in hospital/clinical environments; used by qualified healthcare professionals. Inputs: ECG leads (single or multi-lead). Processing: Arrhythmia analysis, ST segment analysis, and QT/QTc interval measurement. Outputs: Real-time events and alarms for clinicians. Assists in cardiac risk assessment, treatment monitoring, and symptom evaluation. Does not provide diagnostic interpretations for QT measurements. Modification adds QT/QTc monitoring to existing ST/AR platform.

## Clinical Evidence

Bench testing only. System-level performance and safety testing conducted based on hazard analysis. Pass/Fail criteria derived from predicate specifications; results confirmed reliability and performance claims.

## Technological Characteristics

Software-based cardiac monitoring algorithm. Operates on existing Philips ST/AR platform. Features include cardiotach, arrhythmia detection, ST segment analysis, and QT/QTc interval measurement. Connectivity via patient monitoring network. No hardware changes.

## Regulatory Identification

The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.

## Special Controls

*Classification.* Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.

## Predicate Devices

- ST/AR ST and Arrhythmia Software ([K964122](/device/K964122.md))
- ST/AR ST and Arrhythmia Software ([K991773](/device/K991773.md))
- ST/AR ST and Arrhythmia Software ([K001348](/device/K001348.md))
- ST/AR ST and Arrhythmia Software ([K003621](/device/K003621.md))
- ST/AR ST and Arrhythmia Software ([K014261](/device/K014261.md))
- ST/AR ST and Arrhythmia Software ([K021251](/device/K021251.md))
- Philips 2010 Plus Holter for Windows ([K010949](/device/K010949.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows a handwritten text string. The string appears to be a combination of letters and numbers, specifically "K070260". There is also a superscripted fraction "P1/2" to the right of the number. The text is written in a dark ink on a white background.

FEB 2 3 2007

## 9.0 510(k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR §807.92.

- 1. The submitter of this premarket notification is:
Denise Haley Sr. Quality & Regulatory Engineer Ultrasound & Monitoring Systems Philips Medical Systems 3000 Minuteman Road, MS0240 Andover, MA 01810-1099

Tel: 978 659 4358 Fax: 978 659 3819 Email: denise.haley@philips.com

This summary was prepared on 24 January 2007

- 2. The name of this device is the Philips ST/AR ST and Arrhythmia Software, Release H.0. Classification names are as follows:

| Classification | ProCode | Description                            |
|----------------|---------|----------------------------------------|
| 870.1025, II   | 74 MLD  | Monitor, ST Alarm                      |
| 870.1025, II   | 74 DSI  | Arrhythmia Detector and Alarm          |
| None           | 74 MHX  | Physiological Monitor, Patient Monitor |

- The new device is substantially equivalent to the previously cleared ST/AR ST and 3. Arrhythmia Software device marketed pursuant to K964122, K991773, K001348, K003621, K014261 and K021251 and the Philips 2010 Plus Holter for Windows K010949.
- 4. The modification is a software-based change that adds QT/QTc interval monitoring features.
- The new device has the same Indications for Use and Intended Use as the legally marketed న. predicate devices.
- The new device has the same technological characteristics as the legally marketed predicate 6. devices.

{1}------------------------------------------------

- 7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the new device with respect to the predicate. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The results demonstrate that ST/AR Release H.0 meets all defined reliability requirements and performance claims.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes entwined around it. The caduceus is surrounded by a circular border containing the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES . USA". The text is arranged in a circular fashion around the caduceus symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Philips Medical Systems Ms. Denise Haley Sr. Quality and Regulatory Engineer 3000 Minuteman Road Andover, MA 01810

FEB 2 3 2007

Re: K070260

Trade Name: Philips Medical Systems ST/AR ST and Arrhythmia Software, Release H.0 Regulation Number: 21 CFR 870,1025 Regulation Name: Arrhythmia Detector and Alarm (including ST measurement and alarm) Regulatory Class: Class II Product Code: DSI Dated: January 24, 2007 Received: January 26, 2007

Dear Ms. Haley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act 

{3}------------------------------------------------

Page 2 - Ms. Denise Haley

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Prana D. Zuckerman, M.D.

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## 3.1 ODE Indications Statement

## Indications for Use

510(k) Number (if known): Ko70260

Device Name: ____ ST/AR ST and Arrhythmia Software ___________________________________________________________________________________________________________________________

Indications for Use:

Where the clinician decides to monitor cardiac arrhythmia of adult, pediatric, and neonatal patients and/or ST segment of adult patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms.

The intended use of the ST/AR cardiotach is to monitor a neonatal, pediatric, or adult patient's ECG for heart rate and produce events/alarms for one or two ECG leads. The cardiotach function is capable of monitoring both paced and non-paced patients.

The intended use of the ST/AR arthythmia analysis algorithm is to monitor a neonatal, pediatric, or adult patient ECG's for heart rate and ventricular arrhythmias and produce events/alarms for one or two ECG leads. The arrhythmia analysis algorithm is capable of monitoring both paced and non-paced patients.

The intended use of the ST/AR ST analysis algorithm is to monitor an adult patient's ECG for ST segment elevation or depression and produce events/alarms for all possible ECG leads. The ST analysis algorithm is capable of monitoring paced and non-paced adult patients.

The ST algorithm does not analyze ventricularly paced or ventricular ectopic Note: beats.

The intended use of the ST/AR QT/QTc analysis is for use by the physician in the risk assessment process indicated for neonatal, pediatric and adult patients with and without symptoms of arrhythmia. QT measurement is intended to be used by qualified health professionals in hospital or clinical environments. Composite QT (single or multi-lead derived) measures the interval only and is not intended to produce any interpretation or diagnosis of those measurements.

| Prescription Use<br>(Part 21 CFR 801 Subpart D) | ✓ | AND/OR | Over-The-Counter Use<br>(21 CFR 801 Subpart C) |
|-------------------------------------------------|---|--------|------------------------------------------------|
|-------------------------------------------------|---|--------|------------------------------------------------|

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| Division/Sign-O.:    |  |
|----------------------|--|
| Division of Cardiov: |  |

| 510(k) Number | Confidential K070260 |
|---------------|----------------------|
|---------------|----------------------|

Page 10

---

**Source:** [https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DSI/K070260](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DSI/K070260)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com